PTC Therapeutics Announces FDA Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU)

- Broad labeling inclusive of all disease subtypes for individuals 1 month of age and older -

- PTC will host a conference call on Monday, July 28^th at 5:00 pm ET -

Read more at prnewswire.com